Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 26 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Micafungin for Injection. This medication is used to treat various fungal infections and to prevent such infections in patients undergoing stem cell transplants. The drug will be produced at the company's manufacturing facility in Jarod, near Vadodara, India. The press release highlights that Micafungin had significant annual sales in the United States according to market data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases